M
Masaaki Nakayama
Researcher at Tohoku University
Publications - 245
Citations - 8900
Masaaki Nakayama is an academic researcher from Tohoku University. The author has contributed to research in topics: Peritoneal dialysis & Kidney disease. The author has an hindex of 40, co-authored 236 publications receiving 7811 citations. Previous affiliations of Masaaki Nakayama include Fukushima University & International University, Cambodia.
Papers
More filters
Journal ArticleDOI
Review of combination of peritoneal dialysis and hemodialysis as a modality of treatment for end-stage renal disease.
H Fukui,Shigeko Hara,Y Hashimoto,T Horiuchi,M Ikezoe,Noritomo Itami,M Kawabe,Hideki Kawanishi,H Kimura,Y Nakamoto,Masaaki Nakayama,M Ono,K Ota,Toshio Shinoda,T Suga,T Ueda,M Fujishima,T Maeba,Akihiro C. Yamashita,Y Yoshino,S Watanabe +20 more
TL;DR: This therapy allows for the continuation of PD without shifting to total HD in PD patients who continue to have uremic symptoms even after individualization of the PD prescription.
High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment.
Ryo Yamamoto,Masaaki Nakayama,Toshio Hasegawa,Numata Miwako,Hiroyasu Yamamoto,Keitaro Yokoyami,Masato Ikeda,Naohiko Kato,Hiroshi Hayakawa,Hajime Takahashi,Yasushi Otsuka,Yoshindo Kawaguchi,Tastuo Hosoya +12 more
TL;DR: Early development of increased D/P creatinine, classified as HT state, was observed during certain periods on PD in patients who developed EPS after PD withdrawal, which may indicate that HT state of peritoneal membrane is an early marker for EPS, and that the PET is useful to detect patients at high risk of EPS.
Journal ArticleDOI
Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
Keitaro Yokoyama,Takashi Akiba,Masafumi Fukagawa,Masaaki Nakayama,Kenichi Sawada,Yuji Kumagai,Glenn M. Chertow,Hideki Hirakata +7 more
TL;DR: Dose-titrated JTT-751 decreased mean serum phosphate after administration and satisfactorily maintained serum phosphate concentrations throughout the entire duration of the 52-week trial.
Risk factors and preventive measures for encapsulating peritoneal sclerosis--Jikei experience 2002.
Masaaki Nakayama,Hiroyasu Yamamoto,Masato Ikeda,Toshio Hasegawa,Naohiko Kato,Hajime Takahashi,Yasushi Otsuka,Keitaro Yokoyama,Ryo Yamamoto,Yoshindo Kawaguchi,Tastuo Hosoya +10 more
TL;DR: Based on the observational results regarding the risk of EPS development and the characteristic features of patients with EPS, a withdrawal protocol for long-term CAPD patients is established, with the goal of preventing EPS.
Journal ArticleDOI
Combination therapy with peritoneal dialysis and hemodialysis.
TL;DR: The bimodal di-alysis method proposed by McIntyre is noteworthy in that it corrects this disadvantage of HD, but this particular advantage is of no benefit once RRF is lost.